Shares of Bristol Myers Squibb Co. BMY shed 3.84% to $57.42 Thursday, on what proved to be an all-around mixed trading ...

Bristol Myers Squibb is ending work on a handful of assets, including an immunology medication that was in two Phase 3 trials ...

The pharmaceutical company plans to cut $2 billion in annual expenses by the end of 2027 through “operational efficiencies ...

Operator Welcome to the Bristol Myers Squibb fourth quarter 2024 earnings conference call. [Operator instructions] Please note this event is being recorded. I would now like to turn the conference ...

Cobenfy, the main asset acquired through Bristol Myers’ $14 billion purchase of Karuna, had $10 million in sales in the ...

The move comes less than a year after the company attempted to save $1.5 billion through the layoff of some 2,200 employees.

Financial discipline remained a priority, with approximately $1.1 billion of the targeted $1.5 billion in savings already realized. The company has identified an additional $2 billion in savings, with ...

Biotech giant Bristol-Myers Squibb Company BMY is scheduled to report its fourth-quarter and full-year 2024 results on Feb. 6 ...

PHILADELPHIA – Josh Myers couldn’t have picked a worse way to venture into his uncertain future, even if the Green Bay Packers center felt he “got lucky” Sunday. “I thought I broke my leg,” Myers said ...

Add center Josh Myers to the list. Myers suffered a devastating leg injury late in the fourth quarter with the Packers trailing 22-10 in what turned out to be their final offensive possession of ...

Source: FactSet Markets Diary: Data on U.S. Overview page represent trading in all U.S. markets and updates until 8 p.m. See Closing Diaries table for 4 p.m. closing data. Sources: FactSet ...

BMS-986368 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Epilepsy. According to GlobalData, Phase I drugs for Epilepsy have an 84% phase transition success rate ...